Sonrai and Plectonic Biotech partner to advance cancer immunotherapies

Belfast-based AI speciualist Sonrai Analytics Ltd, and German Plectonic Biotech GmbH have annouced they will be collaborating to accelerate the development of Plectonic’s logic-gated antibody Logibody immunotherapy technology across multiple cancer types. As part of the project, Sonrai will apply its advanced AI technology and bioinformatics expertise to identify and validate ultra-specific antigen combinations to guide Plectonic’s tumour-targeting while minimising impact on healthy cells. This synergy aims to fast-track the development of the Logibody platform by combining Sonrai’s cutting-edge data science with Plectonic’s breakthrough DNA nanotechnology.

Using Sonrai’s AI-driven, multi-modal approach, which integrates single-cell RNA sequencing with proteomic mass spectrometry datasets, the study will quantitatively assess antigen co-expression patterns in tumour versus healthy tissues, in both solid and blood cancer indications. This high-resolution approach, powered by Sonrai’s cloud-based advanced analytics platform and integrated bioinformatics pipelines, enables scalable, multi-omics analysis to accelerate target discovery and validation workflows.

At the core of the project is Plectonic’s proprietary Logibody technology – a logic-gated antibody platform that acts as a molecular switch, triggering an antibody-mediated immune response only in the presence of specific tumour antigens. Plectonic Biotech, a spin-out from the Technical University of Munich, has developed a nanoswitch that links immune cells to tumour cells. First, one antibody binds to a tumour target. This activates a second antibody, which then recruits and activates immune cells.

This approach aims to increase treatment precision while reducing toxicity, thereby lowering side effects for patients.

“This project demonstrates the power of AI and multi-modal analysis to tackle complex biomedical challenges, accelerating the development of next-generation immunotherapies.” said Prof. Darragh McArt, CEO and Founder, Sonrai. “We’re honored to support Plectonic as they advance their groundbreaking immunotherapy technology, reflecting our mission to bring safer, more effective cancer treatments to patients.”

“By leveraging Sonrai’s AI platform, we will be able to identify the most promising therapeutic targets and accelerate our path to clinical trials,” said Dr. Klaus Wagenbauer, CEO and Founder, Plectonic Biotech. “This brings us closer to delivering therapies that offer hope to cancer patients while dramatically reducing the burden of treatment-induced side effects.”